# 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo

> **NCT02347072** · PHASE3 · COMPLETED · sponsor: **Pearl Therapeutics, Inc.** · enrollment: 80 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** GFF MDI (PT003)
- **DRUG:** Placebo MDI
- **DRUG:** Spiriva® Respimat® (Tiotropium Bromide)

## Key facts

- **NCT ID:** NCT02347072
- **Lead sponsor:** Pearl Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-01
- **Primary completion:** 2015-08-01
- **Final completion:** 2016-03-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02347072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02347072, "24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02347072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*